Login to Your Account



Clinic Roundup


Monday, July 25, 2011
Taiho Pharmaceutical Co. Ltd., of Tokyo, reported Phase II results showing that its oral nucleoside cancer drug TAS-102 significantly improved overall survival compared to placebo (9 months vs. 6.6 months) and significantly reduced the risk of mortality (p = 0.0011) in patients with refractory metastatic colorectal cancer who had received standard chemotherapy of at least two or more regimens containing a fluoropyrimidine, irinotecan and oxaliplatin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription